TIS 0.00% 0.0¢ tissue therapies limited

Minutes from the Jan Meeting re: Vitrogro What was the CHMP...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 63 Posts.
    Minutes from the Jan Meeting re: Vitrogro

    What was the CHMP recommendation and scientific discussion? And what was the BWP report?

    (EMEA/H/D/002831) ((substance to be reviewed) insulin-like growth factor-i (igf-i) segment), (hard-to-heal wounds, primarily venous leg ulcers) The Committee discussed the issues identified in this application, mainly regarding the benefit / risk of the product as well as the quality control. Furthermore the members discussed some procedural aspects relating to the CE mark classification. The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions. The Committee adopted the BWP Report.
 
watchlist Created with Sketch. Add TIS (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.